Transfection reagent

Monday, 06 August, 2007 | Supplied by: Life Technologies


Lipofectamine LTX Reagent offers a solution for gene expression as it is a plasmid DNA-specific transfection reagent that can provide the same level of reproducible and efficient gene expression in a wide range of cell lines, including primary and disease-related cells. Lipofectamine LTX Reagent is synthesised from 100% animal origin-free components, making it easy to validate the absence of zoonotic diseases, such as BSE or viruses, in experiments or cell lines. A certificate of origin may be obtained.

Lipofectamine LTX Reagent offers: easy optimisation and minimal cytotoxicity; high gene expression; compatibility with a broad range of cell types; and a simple one-tube protocol.

The reagent delivers both high levels of protein expression and lower cytotoxicity in a wide range of cell types. Cell line-specific protocols enable users to optimise any gene expression experiment.

Achieving high levels of target protein expression enables cells to respond to assay conditions, which helps users to obtain relevant data from functional genomics expression studies.

With the ability to transfect a broad range of cell types, including primary and disease-related cells, Lipofectamine LTX Reagent provides a versatile approach for all transient and stable gene expression experiments. Recommended transfection conditions for these cell types are available.

Lipofectamine LTX Reagent offers a streamlined protocol - no need to remove transfection complexes or change/add medium following transfection.

Online: www.invitrogen.com
Phone: 1800 331 627
Related Products

AdipoGen Life Sciences DYRK inhibitors

Leucettinibs provide research tools and potential leads for further optimisation towards...

GroPep Bioreagents IGF-1 Family Proteins

IGF-1 proteins are available in different sizes, and all GroPep Bioreagents are freeze-dried and...

LSBio PathPlus Neuroscience Antibodies

LSBio PathPlus Neuroscience Antibodies are suitable for immunohistochemistry (IHC) applications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd